Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with bortezomib-cyclophosphamide-dexamethasone. This...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2023-07-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/11160
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!